The prospect of combination therapy with immune checkpoint inhibitors and chemotherapy for squamous cell carcinoma of the lung.
作者信息
Ichiki Yoshinobu, Fukuyama Takashi, Nakanishi Kozo
机构信息
Department of General Thoracic Surgery, National Hospital Organization, Saitama Hospital, Wako, Japan.
Second Department of Surgery, University of Occupational and Environmental Health, School of Medicine, Kitakyushu, Japan.
出版信息
Transl Lung Cancer Res. 2020 Jun;9(3):811-815. doi: 10.21037/tlcr.2020.01.14.
Abstract
摘要
相似文献
1
The prospect of combination therapy with immune checkpoint inhibitors and chemotherapy for squamous cell carcinoma of the lung.免疫检查点抑制剂与化疗联合治疗肺鳞状细胞癌的前景。
Transl Lung Cancer Res. 2020 Jun;9(3):811-815. doi: 10.21037/tlcr.2020.01.14.
2
Comparative efficacy and toxicity of immune checkpoint inhibitors in combination with or without chemotherapy treatment for advanced esophageal squamous cell carcinoma: A systematic review and meta-analysis.免疫检查点抑制剂联合或不联合化疗治疗晚期食管鳞状细胞癌的疗效和毒性比较：一项系统评价和荟萃分析
Front Oncol. 2022 Nov 24;12:958783. doi: 10.3389/fonc.2022.958783. eCollection 2022.
3
Baseline C-reactive protein predicts efficacy of the first-line immune checkpoint inhibitors plus chemotherapy in advanced lung squamous cell carcinoma: a retrospective, multicenter study.基线 C 反应蛋白可预测一线免疫检查点抑制剂联合化疗治疗晚期肺鳞癌的疗效：一项回顾性、多中心研究。
BMC Cancer. 2023 Dec 16;23(1):1244. doi: 10.1186/s12885-023-11737-x.
4
Efficacy and safety of first-line treatments with immune checkpoint inhibitors plus chemotherapy for non-squamous non-small cell lung cancer: a meta-analysis and indirect comparison.免疫检查点抑制剂联合化疗作为一线治疗非鳞状非小细胞肺癌的疗效和安全性：一项荟萃分析和间接比较。
Ann Palliat Med. 2021 Mar;10(3):2766-2775. doi: 10.21037/apm-20-1498. Epub 2021 Feb 1.
5
Immune checkpoint inhibitors in lung cancer: current status and future directions.肺癌中的免疫检查点抑制剂：现状与未来方向。
Chin Clin Oncol. 2017 Apr;6(2):17. doi: 10.21037/cco.2017.02.05.
6
Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung.表皮生长因子受体抑制在肺癌鳞状细胞癌治疗中的应用
Oncologist. 2016 Feb;21(2):205-13. doi: 10.1634/theoncologist.2015-0209. Epub 2016 Jan 14.
7
Efficacy and Safety of Immune Checkpoint Inhibitor in Advanced Esophageal Squamous Cell Carcinoma: A Meta-Analysis.免疫检查点抑制剂在晚期食管鳞状细胞癌中的疗效与安全性：一项荟萃分析
Front Oncol. 2021 Dec 21;11:777686. doi: 10.3389/fonc.2021.777686. eCollection 2021.
8
Immune checkpoint inhibitors' combination therapy as first-line treatment in advanced esophageal squamous cell carcinoma: a meta-analysis.免疫检查点抑制剂联合疗法作为晚期食管鳞状细胞癌的一线治疗：一项荟萃分析
J Cancer Res Clin Oncol. 2023 Mar;149(3):933-939. doi: 10.1007/s00432-022-04066-2. Epub 2022 Jun 25.
9
A systematic review and network meta-analysis of first-line immune checkpoint inhibitor combination therapies in patients with advanced non-squamous non-small cell lung cancer.系统评价和网络荟萃分析一线免疫检查点抑制剂联合治疗晚期非鳞状非小细胞肺癌患者。
Front Immunol. 2022 Oct 26;13:948597. doi: 10.3389/fimmu.2022.948597. eCollection 2022.
10
Indirect comparison of sintilimab and other PD-L1 inhibitors for first-line treatment of non-squamous non-small-cell lung cancer.信迪利单抗与其他 PD-L1 抑制剂用于非鳞状非小细胞肺癌一线治疗的间接比较。
Future Oncol. 2022 May;18(15):1896-1905. doi: 10.2217/fon-2021-1336. Epub 2022 Mar 21.
引用本文的文献
1
An analysis of the immunological tumor microenvironment of primary tumors and regional lymph nodes in squamous cell lung cancer.肺鳞状细胞癌原发肿瘤和区域淋巴结免疫肿瘤微环境分析
Transl Lung Cancer Res. 2021 Aug;10(8):3520-3537. doi: 10.21037/tlcr-21-479.
2
A Spatial Quantitative Systems Pharmacology Platform spQSP-IO for Simulations of Tumor-Immune Interactions and Effects of Checkpoint Inhibitor Immunotherapy.用于模拟肿瘤免疫相互作用和检查点抑制剂免疫治疗效果的空间定量系统药理学平台spQSP-IO
Cancers (Basel). 2021 Jul 26;13(15):3751. doi: 10.3390/cancers13153751.
3
Should Lung-Sparing Surgery Be the Standard Procedure for Malignant Pleural Mesothelioma?保留肺组织手术应成为恶性胸膜间皮瘤的标准手术方式吗？
J Clin Med. 2020 Jul 8;9(7):2153. doi: 10.3390/jcm9072153.
本文引用的文献
1
The efficacy of PD-1/PD-L1 inhibitors in advanced squamous-cell lung cancer: a meta-analysis of 3112 patients.PD-1/PD-L1 抑制剂在晚期鳞状细胞肺癌中的疗效：3112 例患者的荟萃分析。
Immunotherapy. 2019 Dec;11(17):1481-1490. doi: 10.2217/imt-2019-0101. Epub 2019 Nov 12.
2
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.阿替利珠单抗联合卡铂加白蛋白紫杉醇化疗与单纯化疗一线治疗转移性非鳞状非小细胞肺癌（IMpower130）：一项多中心、随机、开放标签、III 期临床试验。
Lancet Oncol. 2019 Jul;20(7):924-937. doi: 10.1016/S1470-2045(19)30167-6. Epub 2019 May 20.
3
Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.TP53 突变与晚期非小细胞肺癌免疫检查点抑制剂治疗应答和生存延长的相关性。
Lung Cancer. 2019 Jun;132:65-71. doi: 10.1016/j.lungcan.2019.04.005. Epub 2019 Apr 8.
4
Predictive factors of postoperative survival among patients with pulmonary neuroendocrine tumor.肺神经内分泌肿瘤患者术后生存的预测因素
J Thorac Dis. 2018 Dec;10(12):6912-6920. doi: 10.21037/jtd.2018.11.115.
5
Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?在联合化疗的情况下，哪种免疫疗法是晚期鳞状非小细胞肺癌的最佳选择：抗 PD-1 还是抗 PD-L1？
J Immunother Cancer. 2018 Dec 3;6(1):135. doi: 10.1186/s40425-018-0427-6.
6
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.帕博利珠单抗联合化疗用于鳞状非小细胞肺癌。
N Engl J Med. 2018 Nov 22;379(21):2040-2051. doi: 10.1056/NEJMoa1810865. Epub 2018 Sep 25.
7
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.阿替利珠单抗作为转移性非鳞状 NSCLC 一线治疗药物。
N Engl J Med. 2018 Jun 14;378(24):2288-2301. doi: 10.1056/NEJMoa1716948. Epub 2018 Jun 4.
8
PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project.PD-L1 免疫组织化学在真实临床样本中的可比性研究：Blueprint 阶段 2 项目的结果。
J Thorac Oncol. 2018 Sep;13(9):1302-1311. doi: 10.1016/j.jtho.2018.05.013. Epub 2018 May 22.
9
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.帕博利珠单抗联合化疗治疗转移性非小细胞肺癌。
N Engl J Med. 2018 May 31;378(22):2078-2092. doi: 10.1056/NEJMoa1801005. Epub 2018 Apr 16.
10
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.纳武利尤单抗联合伊匹单抗治疗高肿瘤突变负荷肺癌。
N Engl J Med. 2018 May 31;378(22):2093-2104. doi: 10.1056/NEJMoa1801946. Epub 2018 Apr 16.
Zotero 插件